Advertisement

Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans

  • Mohini RanganathanEmail author
  • Joao P. De Aquino
  • Jose A. Cortes-Briones
  • Rajiv Radhakrishnan
  • Brian Pittman
  • Savita Bhakta
  • Deepak C. D’Souza
Original Investigation

Abstract

Rationale

The catechol-O-methyl transferase (COMT) enzyme has been implicated in determining dopaminergic tone and the effects of delta-9-tetrahydrocannabinol (THC) in the human brain.

Objective

This study was designed to evaluate the effect of (1) a functional polymorphism and (2) acute pharmacological inhibition of COMT on the acute response to THC in humans.

Methods

Sub-study I: The effect of intravenous (IV) THC (0.05 mg/kg) was investigated in 74 healthy subjects genotyped for the COMT rs4680 (Val/Met) polymorphism in a 2-test-day double-blind, randomized, placebo-controlled study. Sub-study II: COMT rs4680 homozygous subjects (Val/Val and Met/Met) from sub-study I received the COMT enzyme inhibitor tolcapone (200 mg) followed by IV THC or placebo on two additional test days. Subjective, behavioral, and cognitive data were obtained periodically on each test day.

Results

Sub-study I: Val/Val individuals were most sensitive to THC-induced attention and working memory deficits. In contrast, the psychotomimetic and subjective effects of THC were not influenced by COMT genotype. Sub-study II: Tolcapone reduced THC-induced working memory deficits, but not THC’s psychotomimetic effects. Tolcapone and COMT genotype (met/met) were associated with an increased report of feeling “mellow.”

Conclusions

The interaction between COMT rs4680 polymorphisms and tolcapone on the cognitive, but not on the psychotomimetic and overall subjective effects of THC, suggests that modulation of dopaminergic signaling may selectively influence specific cannabinoid effects in healthy individuals. The role of dopaminergic signaling in the cognitive effects of cannabinoids should be considered in drug development efforts targeting these effects.

Clinicaltrials.gov registration

https://clinicaltrials.gov/ct2/show/NCT00678730?term=NCT00678730&rank=1

ClinicalTrials.gov Identifier: NCT00678730.

Keywords

COMT THC Cannabis Cannabinoid Dopamine Tolcapone 

Notes

Acknowledgments

We also acknowledge support from the (1) Department of Veterans Affairs, (2) National Institute of Drug Abuse, and (3) National Institute of Alcoholism and Alcohol Abuse.

Funding

Funding and support from R01 DA12382 (Deepak Cyril D’Souza, M.D.), VA Connecticut Healthcare System (VACHS), NARSAD Young Investigator Award 2008 (Savita Bhakta, M.D.) and National Institutes of Mental Health (NIMH) R25 MH071584, “Integrated Mentored Patient-Oriented Research Training (IMPORT) in Psychiatry” (Joao P. De Aquino, M.D.), and Dana Foundation David Mahoney program and CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS) (Rajiv Radhakrishnan, M.D.). Deepak Cyril D’Souza has received in the past 3 years and currently receives research grant support administered through Yale University School of Medicine from Pfizer Inc.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Disclaimer

The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of NIH.

Supplementary material

213_2019_5273_MOESM1_ESM.pdf (157 kb)
Fig. S1 Study Design. Schedule of testing for sub-studies I and II. Sub-study I included 74 individuals of 3 genotypes (Val/Val, Val/Met, Met/Met). THC was administered at time point 0. Sub-study II included 22 homozygote (10 Val/Val, 22 Met/Met) individuals. Tolcapone was administered at time point -90 minutes. THC was administered at time point 0. Subjective and behavioral measures were collected before and after THC administration time points -30, 0 ,+60 and +300 minutes. Cognitive testing was done once approximately 30 minutes after THC administration. (PDF 157 kb)
213_2019_5273_MOESM2_ESM.docx (92 kb)
ESM 1 (DOCX 92 kb)

References

  1. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF (2007) Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 32:1011–1020CrossRefGoogle Scholar
  2. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S (2011) Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 25:1462–1468CrossRefGoogle Scholar
  3. Beaulieu J-M, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182–217CrossRefGoogle Scholar
  4. Behan ÁT, Hryniewiecka M, O'tuathaigh CM, Kinsella A, Cannon M, Karayiorgou M, Gogos JA, Waddington JL, Cotter DR (2012) Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 37:1773–1783CrossRefGoogle Scholar
  5. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD (2014) Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75:470–478CrossRefGoogle Scholar
  6. Bloomfield MA, Ashok AH, Volkow ND, Howes OD (2016) The effects of delta(9)-tetrahydrocannabinol on the dopamine system. Nature 539:369–377CrossRefGoogle Scholar
  7. Bossong MG, Van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, Van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS (2009) [Delta] 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34:759–766CrossRefGoogle Scholar
  8. Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR (2015) Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology 232:2723–2729CrossRefGoogle Scholar
  9. Bossong MG, van Hell HH, Schubart CD, van Saane W, Iseger TA, Jager G, van Osch MJ, Jansma JM, Kahn RS, Boks MP (2019) Acute effects of ∆ 9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype. Eur NeuropsychopharmacolGoogle Scholar
  10. Brunner E, Domhof S, Langer F (2002) Nonparametric analysis of longitudinal data in factorial designs. Wiley, New YorkGoogle Scholar
  11. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117–1127CrossRefGoogle Scholar
  12. Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ (2002) 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. Synapse 43:201–207CrossRefGoogle Scholar
  13. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75:807–821CrossRefGoogle Scholar
  14. Cohen K, Weinstein A (2018) The effects of cannabinoids on executive functions: evidence from cannabis and synthetic cannabinoids—a systematic review. Brain Sci 8:40CrossRefGoogle Scholar
  15. Cosker E, Schwitzer T, Ramoz N, Ligier F, Lalanne L, Gorwood P, Schwan R, Laprévote V (2017) The effect of interactions between genetics and cannabis use on neurocognition. A review. Prog Neuro-Psychopharmacol Biol PsychiatryGoogle Scholar
  16. D’Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T (2008) Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans. Psychopharmacology 198:587–603CrossRefGoogle Scholar
  17. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR (2012) Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72:811–816CrossRefGoogle Scholar
  18. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci 98:6917–6922CrossRefGoogle Scholar
  19. Giakoumaki SG, Roussos P, Bitsios P (2008) Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 33:3058–3068CrossRefGoogle Scholar
  20. Goldman D, Weinberger DR, Malhotra AK, Goldberg TE (2009) The role of COMT Val158Met in cognition. Biol Psychiatry 65:e1–e2CrossRefGoogle Scholar
  21. Heinz A, Smolka MN (2006) The effects of catechol O-methyltransferase genotype on brain activation elicited by affective stimuli and cognitive tasks. Rev Neurosci 17:359–368CrossRefGoogle Scholar
  22. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen H-U, Van Os J (2004) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Bmj 330:11CrossRefGoogle Scholar
  23. Henquet C, Murray R, Linszen D, van Os J (2005) The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31:608–612CrossRefGoogle Scholar
  24. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, van Os J (2006) An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31:2748–2757CrossRefGoogle Scholar
  25. Henquet C, Rosa A, Delespaul P, Papiol S, Fananas L, van Os J, Myin-Germeys I (2009) COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of 'switching on' hallucinations in the flow of daily life. Acta Psychiatr Scand 119:156–160CrossRefGoogle Scholar
  26. Hirvonen M, Nagren K, Rinne J, Pesonen U, Vahlberg T (2009) COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor. Availability in vivo Mol Imaging BiolGoogle Scholar
  27. Htun NC, Miyaki K, Zhao C, Muramatsu M, Sato N (2014) Epistasis effects of COMT and MTHFR on inter-individual differences in mental health: under the inverted U-shaped prefrontal dopamine model. Biochem Biophys Res Commun 451:574–579CrossRefGoogle Scholar
  28. Jorga KM (1998) Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 50:S31–S38CrossRefGoogle Scholar
  29. Kantrowitz JT, Nolan KA, Sen S, Simen AA, Lachman HM, Bowers MB (2009) Adolescent cannabis use, psychosis and catechol-O-methyltransferase genotype in African Americans and Caucasians. Psychiatry Q 80:213–218CrossRefGoogle Scholar
  30. Lazenka MF, Tomarchio AJ, Lichtman AH, Greengard P, Flajolet M, Selley DE, Sim-Selley LJ (2015) Role of dopamine type 1 receptors and dopamine-and cAMP-regulated phosphoprotein Mr 32 kDa in Δ9-tetrahydrocannabinol–mediated induction of ΔFosB in the mouse forebrain. J Pharmacol Exp Ther 354:316–327CrossRefGoogle Scholar
  31. Morgan CJ, Freeman TP, Powell J, Curran HV (2016) AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry 6:e738CrossRefGoogle Scholar
  32. Munafò MR, Smith GD (2018) Robust research needs many lines of evidence. Nature Publishing GroupGoogle Scholar
  33. Muñoz-Arenas G, Paz-Bermúdez F, Báez-Cordero A, Caballero-Florán R, González-Hernández B, Florán B, Daniel Limón I (2015) Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry. Synapse 69:103–114CrossRefGoogle Scholar
  34. Narendran R, Tumuluru D, May MA, Chowdari KV, Himes ML, Fasenmyer K, Frankle WG, Nimgaonkar VL (2016) Cortical dopamine transmission as measured with the [11C] FLB 457–amphetamine PET imaging paradigm is not influenced by COMT genotype. PLoS One 11:e0157867CrossRefGoogle Scholar
  35. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR (2015) The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci 16:305–312CrossRefGoogle Scholar
  36. O'Tuathaigh CMP, Clarke G, Walsh J, Desbonnet L, Petit E, O'Leary C, Tighe O, Clarke N, Karayiorgou M, Gogos JA, Dinan TG, Cryan JF, Waddington JL (2012) Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int J Neuropsychopharmacol 15:1331–1342CrossRefGoogle Scholar
  37. Pelayo-Terán JM, Pérez-Iglesias R, Mata I, Carrasco-Marín E, Vázquez-Barquero JL, Crespo-Facorro B (2010) Catechol-O-methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Res 179:291–296CrossRefGoogle Scholar
  38. Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, Devoto P (2002) Δ 9-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948:155–158CrossRefGoogle Scholar
  39. Prescot AP, Renshaw PF, Yurgelun-Todd DA (2013) γ-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend 129:232–239CrossRefGoogle Scholar
  40. Radhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B (2015) GABA deficits enhance the psychotomimetic effects of Δ9-THC. Neuropsychopharmacology 40:2047–2056CrossRefGoogle Scholar
  41. Ranganathan M, Radhakrishnan R, Addy PH, Schnakenberg-Martin AM, Williams AH, Carbuto M, Elander J, Pittman B, Sewell RA, Skosnik PD (2017) Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Prog Neuro-Psychopharmacol Biol Psychiatry 79:176–183CrossRefGoogle Scholar
  42. Shafa R (2009) Poster 3: Comt-inhibitors may be a promising tool in treatment of marijuana addiction. Am J Addict 18:322Google Scholar
  43. Sherif M, Radhakrishnan R, D’Souza DC, Ranganathan M (2016) Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry 79:526–538CrossRefGoogle Scholar
  44. Spronk DB, Van der Schaaf ME, Cools R, De Bruijn ER, Franke B, van Wel JH, Ramaekers JG, Verkes RJ (2016) Acute effects of cocaine and cannabis on reversal learning as a function of COMT and DRD2 genotype. Psychopharmacology 233:199–211CrossRefGoogle Scholar
  45. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM (2009) Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48:186–190CrossRefGoogle Scholar
  46. Temple EC, Driver M, Brown RF (2014) Cannabis use and anxiety: is stress the missing piece of the puzzle? Front Psychol 5:168Google Scholar
  47. Tunbridge EM, Dunn G, Murray RM, Evans N, Lister R, Stumpenhorst K, Harrison PJ, Morrison PD, Freeman D (2015) Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences. J Psychopharmacol 29:1146–1151CrossRefGoogle Scholar
  48. Vaessen TSJ, de Jong L, Schäfer AT, Damen T, Uittenboogaard A, Krolinski P, Nwosu CV, Pinckaers FME, Rotee ILM, Smeets APW (2018) The interaction between cannabis use and the Val158Met polymorphism of the COMT gene in psychosis: a transdiagnostic meta–analysis. PLoS One 13:e0192658CrossRefGoogle Scholar
  49. Van der Knaap L, Schaefer J, Franken I, Verhulst F, van Oort F, Riese H (2014) Catechol-O-methyltransferase gene methylation and substance use in adolescents: the TRAILS study. Genes Brain Behav 13:618–625CrossRefGoogle Scholar
  50. Verrico CD, Jentsch JD, Roth RH (2003) Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 49:61–66CrossRefGoogle Scholar
  51. Vinkers CH, Van Gastel WA, Schubart CD, Van Eijk KR, Luykx JJ, Van Winkel R, Joels M, Ophoff RA, Boks MP, Genetic R, Investigators OUP, Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D (2013) The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val(1)(5)(8)Met polymorphism. Schizophr Res 150:303–311CrossRefGoogle Scholar
  52. Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, Mannisto PT (2007) Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27:10196–10209CrossRefGoogle Scholar
  53. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O’DONOVAN MC, Owen MJ (2007) Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 191:402–407CrossRefGoogle Scholar

Copyright information

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019

Authors and Affiliations

  • Mohini Ranganathan
    • 1
    • 2
    • 3
    Email author
  • Joao P. De Aquino
    • 1
    • 2
    • 3
  • Jose A. Cortes-Briones
    • 1
    • 2
    • 3
  • Rajiv Radhakrishnan
    • 1
    • 2
    • 3
  • Brian Pittman
    • 1
  • Savita Bhakta
    • 4
  • Deepak C. D’Souza
    • 1
    • 2
    • 3
  1. 1.Department of PsychiatryYale University School of MedicineNew HavenUSA
  2. 2.U.S. Department of Veterans Affairs, Clinical Neurosciences DivisionVA Connecticut Healthcare SystemWest HavenUSA
  3. 3.Clinical Neuroscience Research UnitConnecticut Mental Health CenterNew HavenUSA
  4. 4.Department of PsychiatryUniversity of California San Diego School of MedicineLa JollaUSA

Personalised recommendations